Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial - Takeaways - MDSpire

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial

  • By

  • Akram I. Ahmad

  • Samita Garg

  • Jeffrey Jacobs

  • Zaid Ansari

  • Tasneem Jamal Al-Din

  • Ashraf Almomani

  • Sara Valencia

  • John Vargo

  • Arjun Chatterjee

  • Hassan Siddiki

  • Liang Hong

  • Michael A. Nicolas

  • Alaina Miller

  • Tilak Shah

  • May 1, 2026

  • 0 min

Share

  • 1

    GLP-1 and GIP agonists are effective for type 2 diabetes, weight loss, and improving various health outcomes.

  • 2

    The ASA recommends holding GLP-1 agonists before procedures due to potential risks, despite limited evidence.

  • 3

    The AGA suggests an individualized approach for managing GLP-1 and GIP agonists prior to endoscopic procedures.

  • 4

    This study aimed to evaluate the impact of continuing versus holding GLP-1/GIP agonists on residual gastric volume during endoscopy.

  • 5

    The trial found that continuing GLP-1/GIP agonists did not lead to clinically significant residual gastric volume issues.

Original Source(s)

Holding vs Continuing GLP-1/GIP Agonists Before Upper Endoscopy: The OCULUS Randomized Clinical Trial

  • by Akram I. Ahmad, Samita Garg, Jeffrey Jacobs, Zaid Ansari, Tasneem Jamal Al-Din, Ashraf Almomani, Sara Valencia, John Vargo, Arjun Chatterjee, Hassan Siddiki, Liang Hong, Michael A. Nicolas, Alaina Miller, Tilak Shah

  • May 1, 2026

Related Content

Medical Oddities: Real AI Romance, Where Code Meets Crush

This week the focus is on love and relationships: how it has evolved in society, and it’s effect on the people who live in it.

Special Series eBook: GLP-1 Analysis

Experts explore how analytical science is meeting the challenges shaping GLP-1 therapeutics

  • April 14, 2026

  • 1 min
Advanced Crohn’s Therapies Show Similar Safety

Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.